Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 23c
Tweet
Share
E-mailGet Alerts HOWL Hot Sheet
Join SI Premium – FREE
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.53), $0.23 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $3.75 million.
For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 36c
- inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
- Healthcare Realty Trust (HR) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
